![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, June 28, 2019 12:35:23 PM
Both AC5 and Purastat may not be particularly effective in high volume, high prressure bleeds (AC5 was tested in a trial in a dermatology bleed with saline as a control; pretty weak) other reports are interesting but anecdotal. Bleeding encountered in GI endoscopy is a low flow, low preessure bleed. Both products would seem to be effective in this indication. There are millions of endoscopies annually, with andenomas and polyp removals which cause a little bleeding.
Point here is not to state that Purastat is better than AC5, or vice versa. Both products seem to be roughly equivalent (business reason for patent suit) in efficacy. Question is, Why is 3-D making a push forward and ARTH waiting? Has anyone seen the FDA cleared AC5 product commerce in the US? It was cleared by FDA in December.
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM